SEC Filing Summary: Tharimmune, Inc. (THAR)
Business Context and Reporting Period
This Form 8-K was filed on December 12, 2023, by Tharimmune, Inc., a Delaware corporation listed on The Nasdaq Stock Market LLC under the symbol "THAR." The filing addresses a regulatory compliance matter regarding the company's stock bid price.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than financial performance.
Material Changes and Events
- Nasdaq Compliance Extension: The company previously failed to meet Nasdaq's minimum $1.00 bid price requirement as of June 12, 2023.
- Deadline Extension: On December 12, 2023, Nasdaq granted the company an additional 180 calendar days to regain compliance, extending the deadline to June 10, 2024.
- Compliance Criteria: To close the matter, the closing bid price of the common stock must be at least $1.00 per share for a minimum of 10 consecutive business days during this extension period.
Outlook, Risks, and Management Commentary
The primary risk identified is the potential delisting of the company's common stock if it fails to meet the $1.00 bid price requirement by June 10, 2024. Management has not provided specific financial guidance or commentary on operational outlook in this filing, as the document is limited to the notification of the compliance extension.
Investor Verification Checklist
- Verify the current trading price of THAR stock to assess proximity to the $1.00 threshold.
- Monitor the stock's closing bid price daily to track progress toward the 10 consecutive business days requirement.
- Review subsequent filings for any updates on the company's plan to achieve compliance or potential reverse stock split proposals.
- Confirm the exact expiration date of the compliance period (June 10, 2024).